2023 World Conference on Lung Cancer (Posters)-P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions.

P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions. - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of an international multicentric observational study involving 4 centers from France and Italy. The study focused on the expression of c-MET on the cellular membrane in patients with advanced non-small cell lung cancer (NSCLC) and RET fusions.<br /><br />Tissue specimens from 44 patients with advanced RET NSCLC, who were either treated or untreated with RET inhibitors (RETi), were evaluated for c-MET expression using immunohistochemistry. The results were scored from 0 to 3 based on the intensity of staining in tumor cells.<br /><br />The study found that c-MET was expressed in a high proportion (73%) of the patients with RET NSCLC, at various levels. The expression of c-MET did not impact on the biological features of the tumors, and there was no significant difference in progression-free survival (PFS) and overall survival (OS) between patients with c-MET expression and those without.<br /><br />The study also provided information on the clinico-biological features of the patients, including their age, sex, smoking history, histology, fusion partner, and the type of RETi used.<br /><br />In conclusion, the study suggests that c-MET is frequently expressed on the membrane in RET NSCLC and may be a potential target for novel treatment strategies. However, further exploration is needed to fully understand its role. The expression of c-MET did not have a significant impact on the efficacy of RETi therapy.<br /><br />Overall, this study provides valuable insights into the expression of c-MET in patients with advanced RET NSCLC and highlights the need for further research in this area.

Asset Subtitle

Arianna Marinello

Meta Tag

Speaker Arianna Marinello

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

international multicentric study

c-MET expression

advanced NSCLC

RET fusions

RET inhibitors

immunohistochemistry

biological features

progression-free survival

clinico-biological features

novel treatment strategies